Table 5.

Adverse events considered relevant to treatment.

	Induction phase			Maintenance phase
Adverse events	Cet group n = 78 (54.5%)	Bev group n = 63 (44.1%)	P-value	Cet group n = 78 (54.5%)	Bev group n = 63 (44.1%)	P-value
Leucopenia			0.74			–
Grade 1–2	54 (69.2)	37 (58.7)		16 (20.5)	11 (17.5)
Grade 3–4	5 (6.4)	5 (7.9)		0 (0.0)	0 (0.0)
Anemia			1.00			0.09
Grade 1–2	22 (28.2)	17 (27.0)		7 (9.0)	11 (17.5)
Grade 3–4	2 (2.6)	1 (1.6)		3 (3.8)	0 (0.0)
Neutropenia			0.55			0.16
Grade 1–2	35 (44.9)	28 (44.4)		15 (19.2)	9 (14.3)
Grade 3–4	24 (30.8)	15 (23.8)		0 (0.0)	2 (3.2)
Thrombocytopenia			1.00			–
Grade 1–2	16 (20.5)	14 (22.2)		6 (7.7)	13 (20.6)
Grade 3–4	1 (1.3)	0 (0.0)		0 (0.0)	0 (0.0)
Hypertension			0.11			0.20
Grade 1–2	17 (21.8)	16 (25.4)		7 (9.0)	5 (7.9)
Grade 3–4	1 (1.3)	6 (9.5)		0 (0.0)	3 (4.8)
Abnormal liver function			1.00			1.00
Grade 1–2	52 (66.7)	37 (58.7)		25 (32.1)	16 (25.4)
Grade 3–4	1 (1.3)	1 (1.6)		1 (1.3)	1 (1.6)